Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.
作者信息
Abdul-Aziz Mohd H, Lipman Jeffrey, Roberts Jason A
机构信息
Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Building 71/918 Royal Brisbane & Women's Hospital, Brisbane, QLD, 4029, Australia.
School of Pharmacy, International Islamic University Malaysia, Kuantan, Malaysia.
出版信息
Crit Care. 2017 Nov 21;21(1):283. doi: 10.1186/s13054-017-1871-2.
Abstract
摘要
相似文献
1
Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.识别重症感染重症患者中β-内酰胺类药物暴露欠佳的“高危”患者。
Crit Care. 2017 Nov 21;21(1):283. doi: 10.1186/s13054-017-1871-2.
2
Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization.危重症患者的肾脏清除率增加：病因、定义及其对β-内酰胺类药物剂量优化的影响
Curr Opin Pharmacol. 2015 Oct;24:1-6. doi: 10.1016/j.coph.2015.06.002. Epub 2015 Jun 25.
3
Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.β-内酰胺类抗生素的长期给药——全面综述与批判性评价
Swiss Med Wkly. 2016 Oct 10;146:w14368. doi: 10.4414/smw.2016.14368. eCollection 2016.
4
Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.β-内酰胺类抗生素在危重症患者中的药代动力学和药效学。
Farm Hosp. 2022 Mar 26;46(3):182-190.
5
Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.β-内酰胺类抗生素治疗药物监测对连续性肾脏替代治疗危重症患者剂量调整的影响。
Int J Antimicrob Agents. 2017 May;49(5):589-594. doi: 10.1016/j.ijantimicag.2017.01.009. Epub 2017 Mar 21.
6
Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.β-内酰胺类抗生素治疗革兰氏阴性感染的延长输注：原理和证据基础。
Curr Opin Infect Dis. 2020 Dec;33(6):501-510. doi: 10.1097/QCO.0000000000000681.
7
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.危重症患者β-内酰胺类药物的治疗药物监测：概念验证。
Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.
8
Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.增加β-内酰胺类药物剂量方案可改善因医院或呼吸机获得性肺炎首发病例而接受治疗的伴有急性肾损伤清除率增加的危重症患者的临床结局：一项前后对照研究。
Crit Care. 2019 Nov 27;23(1):379. doi: 10.1186/s13054-019-2621-4.
9
Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?优化危重症患者β-内酰胺类药物治疗的药代动力学/药效学目标：首剂常规剂量是否有效？
Expert Rev Anti Infect Ther. 2017 Jul;15(7):677-688. doi: 10.1080/14787210.2017.1338139. Epub 2017 Jun 19.
10
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.在某些危重症患者中初始β-内酰胺类药物浓度低于治疗范围：增强的肾脏清除率与低药物谷浓度之间的关系。
Chest. 2012 Jul;142(1):30-39. doi: 10.1378/chest.11-1671.
引用本文的文献
1
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.哌拉西林-他唑巴坦与美罗培南优化的药代动力学/药效学目标达成对接受持续输注单药治疗确诊革兰阴性血流感染和/或呼吸机相关性肺炎的重症患者序贯器官衰竭评估（SOFA）评分及炎症生物标志物随时间变化趋势的比较影响
Antibiotics (Basel). 2024 Mar 25;13(4):296. doi: 10.3390/antibiotics13040296.
2
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Bloodstream Infections and/or Ventilator-Associated Pneumonia?对于持续输注哌拉西林-他唑巴坦，优化的联合药代动力学/药效学靶点达成能否成为一种有价值的创新方法，即使在治疗有确诊产超广谱β-内酰胺酶血流感染和/或呼吸机相关性肺炎的重症患者时，也能使单药治疗效果最大化？
Antibiotics (Basel). 2023 Dec 14;12(12):1736. doi: 10.3390/antibiotics12121736.
3
Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation Therapy.2 例体外膜肺氧合治疗患儿的头孢曲松药代动力学和药效学
Ther Drug Monit. 2023 Dec 1;45(6):832-836. doi: 10.1097/FTD.0000000000001133. Epub 2023 Sep 12.
4
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.群体药代动力学和目标达成分析，以确定危重症患者头孢吡肟的合理经验性给药策略。
J Antimicrob Chemother. 2023 Jun 1;78(6):1460-1470. doi: 10.1093/jac/dkad106.
5
Pharmacokinetic parameters over time during sepsis and the association of target attainment and outcomes in critically ill children and young adults receiving ceftriaxone.脓毒症期间的药代动力学参数随时间的变化，以及接受头孢曲松治疗的危重症儿童和青年患者的达标情况与结局的相关性。
Pharmacotherapy. 2023 Jul;43(7):609-621. doi: 10.1002/phar.2774. Epub 2023 Feb 14.
6
Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.使用群体药代动力学建模和目标达成分析评估 ICU 患者美罗培南的经验性给药方案。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0131222. doi: 10.1128/aac.01312-22. Epub 2023 Jan 9.
7
Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.不同肾功能重症患者新型抗生素的用药方案：快速综述
Antibiotics (Basel). 2022 Apr 20;11(5):546. doi: 10.3390/antibiotics11050546.
8
Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients.美罗培南风险计算器的评估：一种用于预测重症患者美罗培南目标未达成风险的用户友好型工具
Antibiotics (Basel). 2021 Apr 20;10(4):468. doi: 10.3390/antibiotics10040468.
9
Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment.重症监护患者中严重坏死性软组织感染的强化多学科管理：一种提高治疗效果的协作方法。
Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1153-1162. doi: 10.1007/s10096-019-03521-2. Epub 2019 Mar 6.
本文引用的文献
1
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.肾功能在标准剂量美罗培南治疗危重症患者后目标未达标风险评估中的作用：一项前瞻性观察研究。
Crit Care. 2017 Oct 21;21(1):263. doi: 10.1186/s13054-017-1829-4.
2
Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.优化重症脓毒症的澳大利亚土著危重症患者美罗培南剂量。
Int J Antimicrob Agents. 2016 Nov;48(5):542-546. doi: 10.1016/j.ijantimicag.2016.08.015. Epub 2016 Sep 29.
3
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.重症患者美罗培南的群体药代动力学及达标概率
Eur J Clin Pharmacol. 2016 Jul;72(7):839-48. doi: 10.1007/s00228-016-2053-x. Epub 2016 Apr 6.
4
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.增强的肾功能清除率、β-内酰胺类药物低浓度与危重症患者的临床结局：一项观察性前瞻性队列研究。
Int J Antimicrob Agents. 2015 Apr;45(4):385-92. doi: 10.1016/j.ijantimicag.2014.12.017. Epub 2015 Jan 19.
5
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.在重症患者中应用药代动力学/药效学原理：优化疗效并减少耐药性产生。
Semin Respir Crit Care Med. 2015 Feb;36(1):136-53. doi: 10.1055/s-0034-1398490. Epub 2015 Feb 2.
6
Comparison of different equations to assess glomerular filtration in critically ill patients.比较不同方程评估危重症患者肾小球滤过率。
Intensive Care Med. 2015 Mar;41(3):427-35. doi: 10.1007/s00134-014-3641-9. Epub 2015 Jan 27.
7
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.个体化抗生素剂量给药用于危重症患者：挑战与潜在解决方案。
Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24.
8
Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.2000-2012 年澳大利亚和新西兰重症监护病房严重脓毒症和脓毒性休克患者的死亡率。
JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
9
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?DALI 研究：确定重症监护病房患者的抗生素水平：目前的β-内酰胺类抗生素剂量是否足以满足重症患者的需求？
Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
10
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.在某些危重症患者中初始β-内酰胺类药物浓度低于治疗范围：增强的肾脏清除率与低药物谷浓度之间的关系。
Chest. 2012 Jul;142(1):30-39. doi: 10.1378/chest.11-1671.
Zotero 插件